VanEck Biotech ETF
BBH
84 hedge funds and large institutions have $67.4M invested in VanEck Biotech ETF in 2018 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 20 increasing their positions, 22 reducing their positions, and 14 closing their positions.
13% more call options, than puts
Call options by funds: $777K | Put options by funds: $689K
0% more funds holding
Funds holding: 84 → 84 (0)
0% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 14
9% less repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 22
2.38% less ownership
Funds ownership: 20.24% → 17.86% (-2.4%)
23% less capital invested
Capital invested by funds: $87.5M → $67.4M (-$20.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$2.15M |
| 2 |
Rockefeller Capital Management
New York
|
+$1.37M |
| 3 |
Wells Fargo
San Francisco,
California
|
+$1.27M |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$922K |
| 5 |
VF
Virtu Financial
New York
|
+$712K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$4.25M |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$3.65M |
| 3 |
RJFSA
Raymond James Financial Services Advisors
St. Petersburg,
Florida
|
-$1.21M |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$574K |
| 5 |
CWM
Cornerstone Wealth Management
St. Peters,
Missouri
|
-$511K |
BBH Hedge Fund Activity: Q4 2018 in Review
84 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in VanEck Biotech ETF (BBH) for Q4 2018, worth a combined $67.4M — down 23% from $87.5M a quarter earlier.
Fund positioning in BBH was balanced in Q4 2018: 14 funds opened new positions, 14 closed out, 20 added to existing stakes and 22 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $2.15M. The largest seller was Susquehanna International Group, cutting an estimated $4.25M.
- 84 institutional investors held VanEck Biotech ETF (BBH) as of Q4 2018, unchanged from Q3 2018.
- Funds reported $67.4M of VanEck Biotech ETF stock for Q4 2018, down 23% quarter-over-quarter.
- 14 funds opened new VanEck Biotech ETF positions in Q4 2018 and 14 closed out, a net change of 0 holders.
- The largest VanEck Biotech ETF buyer in Q4 2018 was Citadel Advisors, an estimated $2.15M added.
- The largest VanEck Biotech ETF seller in Q4 2018 was Susquehanna International Group, an estimated $4.25M sold.
Based on aggregated 13F filings for Q4 2018.